Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Oyster brings Eli Lilly into $60m round

2 min read
18:53UTC

Oyster Therapeutics, formerly Kesmalea, closed a $60m Series A led by 4BIO Capital, with Eli Lilly joining as a new strategic investor.

TechnologyAssessed
Key takeaway

Eli Lilly joined a second British biotech round in five days as a minority investor.

Oyster Therapeutics, formerly Kesmalea, closed a $60m Series A on Tuesday 10 November led by London's 4BIO Capital, with Eli Lilly joining as a new strategic investor⁠1. Oyster makes protein degraders, drugs that tag a faulty protein for the cell's own disposal system, aimed at tau, the protein that tangles inside nerve cells in Alzheimer's disease.

Lilly put money into two British biotech rounds in five days, the other being T-Therapeutics' Series B, both times as a minority investor behind a specialist lead. A drugmaker buying in at Series A and Series B gets an early view of clinical data, and a seat near any later licensing talks, without setting the price. Licensing is where the money moves later: AstraZeneca paid C4X Discovery a milestone in September when a licensed compound entered its first human trial.

Deep Analysis

In plain English

In Alzheimer's disease, a protein called tau forms tangles inside brain cells, and those cells then die. Oyster Therapeutics is designing drugs called protein degraders. They attach a tag to tau so the cell's own rubbish-disposal system breaks it down. The company has raised $60m to move towards testing in people. Eli Lilly, an American drug company that already sells an Alzheimer's treatment, is one of the new investors.

Deep Analysis
Root Causes

Protein degraders are usually large molecules, which struggle to cross the barrier that protects the brain from the bloodstream. Oyster's bet is that smaller degraders can get through, which is why brain disease has been slower to attract this technology than cancer.

Eli Lilly sells Kisunla, an antibody that clears amyloid, the other protein linked to Alzheimer's. A stake in a tau programme gives Lilly an early view of the next mechanism without building it in-house.

The investor list spans Britain, the United States and Japan, including TOHO Ventures, managed by Global Brain. Brain-disease biotech needs that breadth because few specialist funds will carry a programme alone to first human data.

What could happen next?
  • Opportunity

    Positive animal data on brain entry could lead Lilly to seek a licensing deal for Oyster's tau programme.

  • Risk

    Earlier anti-tau failures mean investors may need early human evidence of benefit before funding later trials.

First Reported In

Update #17 · Founders' relief built for 600 a year

BioIndustry Association· 14 Nov 2026
Read original →
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.